Selected research
Industry Research
Respiratory Drugs Industry Research Report 2026
Market perspective
The global Respiratory Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Respiratory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Respiratory Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Respiratory Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Respiratory Drugs include Abbott, Pfizer, Amgen, Amgen, Horizon Pharma, FibroGen, Dr. Reddy's Laboratories, Dainippon Sumitomo and Afferent Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Respiratory Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Drugs Market by Company
Abbott
Pfizer
Amgen
Amgen
Horizon Pharma
FibroGen
Dr. Reddy's Laboratories
Dainippon Sumitomo
Afferent Pharmaceuticals
Respiratory Drugs Segment by Type
Asthma
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
Chronic Obstructive Pulmonary Disease
Respiratory Drugs Segment by Application
Ambulatory Care
Hospitals
Others
Respiratory Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Asthma
- Idiopathic Pulmonary Fibrosis
- Cystic Fibrosis
- Chronic Obstructive Pulmonary Disease
Applications
- Ambulatory Care
- Hospitals
- Others
Companies covered
- Abbott
- Pfizer
- Amgen
- Amgen
- Horizon Pharma
- FibroGen
- Dr. Reddy's Laboratories
- Dainippon Sumitomo
- Afferent Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Respiratory Drugs Market Size (2021-2032)
- 2.2.2 Global Respiratory Drugs Sales (2021-2032)
- 2.2.3 Global Respiratory Drugs Market Average Price (2021-2032)
- 2.3 Respiratory Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Asthma
- 2.3.3 Idiopathic Pulmonary Fibrosis
- 2.3.4 Cystic Fibrosis
- 2.3.5 Chronic Obstructive Pulmonary Disease
- 2.4 Respiratory Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ambulatory Care
- 2.4.3 Hospitals
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Respiratory Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Respiratory Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Respiratory Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Respiratory Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Respiratory Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Respiratory Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Respiratory Drugs, Product Type & Application
- 3.8 Global Manufacturers of Respiratory Drugs, Established Date
- 3.9 Global Respiratory Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Respiratory Drugs Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Respiratory Drugs Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Amgen
- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Respiratory Drugs Product Portfolio
- 4.3.5 Amgen Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Respiratory Drugs Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Horizon Pharma
- 4.5.1 Horizon Pharma Company Information
- 4.5.2 Horizon Pharma Business Overview
- 4.5.3 Horizon Pharma Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Horizon Pharma Respiratory Drugs Product Portfolio
- 4.5.5 Horizon Pharma Recent Developments
- 4.6 FibroGen
- 4.6.1 FibroGen Company Information
- 4.6.2 FibroGen Business Overview
- 4.6.3 FibroGen Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 FibroGen Respiratory Drugs Product Portfolio
- 4.6.5 FibroGen Recent Developments
- 4.7 Dr. Reddy's Laboratories
- 4.7.1 Dr. Reddy's Laboratories Company Information
- 4.7.2 Dr. Reddy's Laboratories Business Overview
- 4.7.3 Dr. Reddy's Laboratories Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Dr. Reddy's Laboratories Respiratory Drugs Product Portfolio
- 4.7.5 Dr. Reddy's Laboratories Recent Developments
- 4.8 Dainippon Sumitomo
- 4.8.1 Dainippon Sumitomo Company Information
- 4.8.2 Dainippon Sumitomo Business Overview
- 4.8.3 Dainippon Sumitomo Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Dainippon Sumitomo Respiratory Drugs Product Portfolio
- 4.8.5 Dainippon Sumitomo Recent Developments
- 4.9 Afferent Pharmaceuticals
- 4.9.1 Afferent Pharmaceuticals Company Information
- 4.9.2 Afferent Pharmaceuticals Business Overview
- 4.9.3 Afferent Pharmaceuticals Respiratory Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Afferent Pharmaceuticals Respiratory Drugs Product Portfolio
- 4.9.5 Afferent Pharmaceuticals Recent Developments
5 Global Respiratory Drugs Market Scenario by Region
- 5.1 Global Respiratory Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Respiratory Drugs Sales by Region: 2021-2032
- 5.2.1 Global Respiratory Drugs Sales by Region: 2021-2026
- 5.2.2 Global Respiratory Drugs Sales by Region: 2027-2032
- 5.3 Global Respiratory Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Respiratory Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Respiratory Drugs Revenue by Region: 2027-2032
- 5.4 North America Respiratory Drugs Market Facts & Figures by Country
- 5.4.1 North America Respiratory Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Respiratory Drugs Sales by Country (2021-2032)
- 5.4.3 North America Respiratory Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Respiratory Drugs Market Facts & Figures by Country
- 5.5.1 Europe Respiratory Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Respiratory Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Respiratory Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Respiratory Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Respiratory Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Respiratory Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Respiratory Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Respiratory Drugs Market Facts & Figures by Country
- 5.7.1 South America Respiratory Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Respiratory Drugs Sales by Country (2021-2032)
- 5.7.3 South America Respiratory Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Respiratory Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Respiratory Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Respiratory Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Respiratory Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Respiratory Drugs Sales by Type (2021-2032)
- 6.1.1 Global Respiratory Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Respiratory Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Respiratory Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Respiratory Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Respiratory Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Respiratory Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Respiratory Drugs Sales by Application (2021-2032)
- 7.1.1 Global Respiratory Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Respiratory Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Respiratory Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Respiratory Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Respiratory Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Respiratory Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Respiratory Drugs Value Chain Analysis
- 8.1.1 Respiratory Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Respiratory Drugs Production Mode & Process
- 8.2 Respiratory Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Respiratory Drugs Distributors
- 8.2.3 Respiratory Drugs Customers
9 Global Respiratory Drugs Analyzing Market Dynamics
- 9.1 Respiratory Drugs Industry Trends
- 9.2 Respiratory Drugs Industry Drivers
- 9.3 Respiratory Drugs Industry Opportunities and Challenges
- 9.4 Respiratory Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst